Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 7/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 7/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 7/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 7/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 7/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5915359 | 1.00 | ACHE (1.00) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5915351 | 0.93 | ACHE (0.87) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5915290 | 0.93 | ACHE (0.87) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13248930 | 0.84 | ACHE (1.00) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13069242 | 0.84 | ACHE (1.00) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19392468 | 0.84 | ACHE (1.00) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9144277 | 0.84 | PSEN1 (0.72) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2221432 | 0.84 | PSEN1 (0.72) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12793076 | 0.83 | ACHE (0.73) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2220964 | 0.82 | PSEN1 (0.70) | ACHEPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| EP-1758895-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2006009734-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | ACHE 13/4885PSEN1 4/4885PSEN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.